Physician

John W Eklund, MD

According to 2025 Medicare claims, John Eklund, MD (NPI: 1174510523) practices hematology/oncology in the Chicago-Naperville-Schaumburg, IL market, with the plurality of this provider's patient population coming from Cook, IL. This provider's primary affiliated billing organization is ILLINOIS CANCER SPECIALISTS (NPI: 1164483913; TIN: 363980044) and primary practice location at 60714-5906.

Eklund's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 448 traditional Medicare patients, billed 168,598 HCPCS/CPT codes, and received $2,651,673 in Medicare payments. The top billing code was A9552 (Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries). Part D data shows 1,962 prescription claims across 244 beneficiaries totaling $5,494,472 in drug costs, led by Calquence (Acalabrutinib Maleate). 2021 DME data shows 67 claims. Open Payments data shows 122 records totaling $4,962. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,122,056 to $5,494,472. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $3,591 to $698.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	424	105,694	$2,051,044
2016	424	111,961	$2,272,410
2017	403	105,230	$1,853,902
2018	484	130,891	$1,977,246
2019	488	191,497	$2,674,254
2020	416	131,225	$2,524,842
2021	457	142,558	$2,851,897
2022	436	141,252	$2,539,064
2023	427	148,991	$2,706,351
2024	448	168,598	$2,651,673

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	138	995	$1,122,056
2016	143	900	$1,005,948
2017	177	1,297	$1,423,453
2018	183	1,230	$1,864,416
2019	208	1,309	$2,594,277
2020	198	1,334	$2,670,348
2021	216	1,392	$2,859,035
2022	215	1,488	$3,365,984
2023	254	1,680	$3,589,081
2024	244	1,962	$5,494,472

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	21	$821
2016	N/R	29	$1,041
2017	11	74	$16,123
2018	N/R	100	$11,381
2019	N/R	22	$2,289
2020	N/R	30	$3,209
2021	N/R	67	$24,709
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	63	79	$408
96413	Administration of chemotherapy into vein, 1 hour or less	63	309	$104
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	159	477	$100
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	105	306	$97
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	230	498	$69

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Calquence	Acalabrutinib Maleate	60	1,980	$941,517
Brukinsa	Zanubrutinib	53	1,590	$817,057
Revlimid	Lenalidomide	38	1,052	$518,645
Imbruvica	Ibrutinib	27	768	$440,703
Pomalyst	Pomalidomide	26	728	$336,331

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	120	$2,827	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$2,135	E.R. Squibb & Sons, L.L.C.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for John W. Eklund, MD?

Tedicare shows public-source Medicare data for John W. Eklund, MD (NPI 1174510523), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does John W. Eklund, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to John W. Eklund, MD?

John W. Eklund, MD is linked to ILLINOIS CANCER SPECIALISTS (billing NPI 1164483913) in the available physician profile data.

Does John W. Eklund, MD have Open Payments data?

John W. Eklund, MD has 122 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.